- Tytuł:
- 186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC)
- Autorzy:
- Źródło:
- In ESMO Open May 2023 8(1) Supplement 4
Czasopismo naukowe